Abstract. The evidence for increased oxidative stress and DNA damage in amyotrophic lateral sclerosis (ALS) prompted studies to determine if the expression of poly(ADP-ribose) polymerase (PARP) is increased in ALS. Using Western analyses of postmortem tissue, we demonstrated that PARP-immunoreactivity (PARP-IR) was increased 3-fold in spinal cord tissues of sporadic ALS (sALS) patients compared with non-neurological disease controls. Despite the increased PARP-IR, PARP mRNA expression was not increased significantly. Immunohistochemical analyses revealed PARP-IR was increased in both white and gray matter of sALS spinal cord. While PARP-IR was predominantly seen in astrocytes, large motor neurons displayed reduced staining compared with controls. This result contrasts sharply to the staining of Alzheimer and MPTPinduced Parkinson diseased tissue, where poly(ADP-ribose) (PAR)-IR was seen mostly in neurons, with little astrocytic staining. PARP-IR was increased in the pellet fraction of sALS homogenates compared with control homogenates, representing potential PARP binding to chromatin or membranes and suggesting a possible mechanism of PARP stabilization. The present results demonstrate glial alterations in sALS spinal cord tissue and support the role of glial alterations in sALS pathogenesis.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a progressive fatal neurodegenerative disease involving both upper and lower motor neurons (1) . While the molecular mechanisms that underlie motor neuron death in this disease are incompletely understood, oxidative stress is a prominent feature in sporadic ALS (sALS) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Markers of protein and lipid oxidation are elevated in postmortem tissue of sALS (2-5, 7, 8, 14) . In addition, the level of 8-hydroxy-2Ј-deoxyguanosine (8OH2ЈdG), a marker of oxidative injury of DNA, increases with disease progression (7) and correlates with disease severity (11) . These alterations were originally presumed to be largely confined to neurons. However, recent studies with spinal cords of sALS patients or ALS animal models demonstrate that markers of oxidative stress have been localized not only to motor neurons but also astrocytes, microglia, and macrophages (8, (14) (15) (16) (17) (18) .
DNA damage by oxidation, alkylation, or ionizing radiation is associated with activation of poly(ADP-ribose) polymerase (PARP) (19) (20) (21) (22) (23) (24) (25) . PARP is an abundant nuclear protein with a range of functions, including regulation of DNA repair, cell differentiation, and gene expression (26) . When PARP is activated by DNA strand breaks, it subsequently transfers branched chains of ADPribose to a variety of nuclear proteins, including PARP itself (27) . PARP can also be activated by inositol 1,4,5,-triphosphate-Ca ϩϩ mobilization without DNA damage (28) . Ca ϩϩ promotes activation of PARP and Ca ϩϩ is an activating factor in PARP-mediated cell killing (24, 29) . Although PARP facilitates DNA repair (30) , excessive PARP activation can cause massive consumption of its substrate NAD ϩ , with resulting cell death due to energy depletion (19-21, 24, 27, 31-33) .
Recently, the participation of PARP has been emphasized as a pathogenic mechanism in MPTP-induced Parkinson disease (34) (35) (36) (37) , Alzheimer disease (38) , ischemic brain injury (39) (40) (41) (42) (43) (44) , and CNS trauma (45) . Furthermore, PARP inhibitors have been proposed as potential therapies in neurodegenerative diseases in which oxidative stress is suspected to play an important pathogenic role (20, 23, 25, 34-37, 40-42, 46, 47) . Despite the ample evidence for oxidative stress in the pathogenesis of ALS, the participation of PARP has not been carefully examined in this disorder.
PARP IMMUNOREACTIVITY IN sALS SPINAL CORD
J Neuropathol Exp Neurol, Vol 62, January, 2003 In this study, we investigated PARP immunoreactivity (PARP-IR) by Western analyses of postmortem spinal cord tissue from sALS patients compared with non-neurological disease controls. Semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was utilized to determine if the difference was due to an alteration in transcriptional regulation. Additionally, immunohistochemical analysis employing dual antibody labeling was used to determine the cell types expressing PARP-IR in sALS spinal cord.
MATERIALS AND METHODS

Postmortem Tissue of sALS and Control Patients
Spinal cord specimens were obtained at autopsy of sALS patients followed in the MDA/ALS Clinic at Baylor College of Medicine, Houston, TX (n ϭ 7) or from the Brain Bank at the University Maryland, Baltimore, Maryland (n ϭ 4). The clinical diagnosis was confirmed pathologically for all sALS patients. Postmortem samples from spinal cords of individuals with nonneurological diseases (n ϭ 9) were used as controls. No pathological changes were present in the spinal cords of the control patients. The cause of death for patients in the sALS and control groups is shown in the Table. There was no significant difference between the average age of the patients in the sALS group (58.8 Ϯ 12.7 yr) and the control group (57.9 Ϯ 15.8 yr; p Ͼ 0.4; Table) or between the average time postmortem of the patients in the sALS group (13.4 h) and the control groups (13.7 h; Table) . Sections from various levels of the spinal cords from each patient were either fixed in formaldehyde and embedded in paraffin, or were immediately frozen in liquid N 2 and stored at Ϫ80ЊC.
Western Blot Analysis
Approximately 300 g samples were taken from the frozen spinal cord specimens without thawing. Whole spinal cord samples or dissected white and gray matter regions were homogenized on ice with a Wheatman homogenizer in a 20-mM HE-PES buffer, pH 7.6, containing 200 mM KCl, 2 mM EGTA, 2 mM EDTA, 10 mM sodium molybdate, 50 mM sodium fluoride, 2 mM sodium pyrophosphate, 1 mM sodium vanadate, 0.1% NP-40, 10% glycerol, 4 mM benzamidine, 15 g/ml aprotinin, 50 M leupeptin, 1 M pepstatin, and 1 mM phenylmethyl-sulfonyl fluoride. The homogenized samples were sonicated twice with Sonic 300 Dismembrator (Artek, Farmingdale, NY) for 20 s. Protein content was measured by the Bradford method (BioRad, Hercules, CA).
Two fractionation studies were performed. In the first fraction study, homogenized samples from each subject were divided in half; one half of the homogenized sample was used for PARP-IR and the second half was centrifuged for 30 min at 14,000 rpm (ϳ15,000 g) at 4ЊC to separate the soluble and pellet fractions. The pellet fraction was dissolved in a buffer containing 0.5 M Tris, 4% SDS, 10% ␤-mercaptoethanol. Thus, 150 g of total homogenate protein, 150 g of soluble protein, and 150 g of pellet protein were loaded on the gel. In the second fraction study, two 250-g protein aliquots of the homogenized samples from each subject were used. One aliquot of the homogenized sample was used for PARP-IR and the other aliquot was centrifuged for 30 min at 14,000 rpm (ϳ15,000 g) at 4ЊC to separate the soluble and pellet fractions. The pellet fractions were dissolved in a buffer containing 0.5 M Tris, 4% SDS, 10% ␤-mercaptoethanol. The entire soluble and pellet fractions and the 250-g total homogenate aliquot were each loaded on the gel.
PARP and caspase 3 immunoreactivities were determined by immunoblot analyses. PARP was detected using the purified mouse anti-human PARP monoclonal antibodies 7D3-6 and C2-10 (Pharmingen, San Diego, CA). Goat polyclonal antibody, CPP32 (R&D systems, Minneapolis, MN) and rabbit polyclonal antibody, CM 1 (IDUN Pharmaceuticals, La Jolla, CA) were used to detect caspase-3. CPP32 was used to demonstrate both pro-caspase-3 and activated-caspase-3, while CM 1 (48, 49) detected only the activated form of caspase-3. Samples from sALS and control patients were subjected to 8% (for PARP), or to 4%-15% (for caspase-3) gradient sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes.
The nitrocellulose membranes were blocked for 1 to 2 h at room temperature (RT) with 5% powdered milk in phosphate buffer saline containing 0.05% Tween-20 (PBST), then individually probed according to the manufacturer's recommendations for either PARP (1:1,000 for 7D3-6 and C2-10) or caspase-3 (1:1,000-2,000 for CPP32 and CM 1 ) overnight at 4ЊC. The membranes were processed using horseradish peroxidase-conjugated anti-mouse, anti-rabbit, or anti-goat secondary antibodies, and their signals detected using ECL chemiluminescence (Amersham Pharmacia, Piscataway, NJ). Sample loading and electroblotting in each experiment were evaluated by stripping the membranes (Reprobe, Geno Technology Inc., St. Louis, MO) and reprobing the membranes with an antibody to actin (A4700; Sigma, St. Louis, MO). The negatives were scanned with an HP ScanJet 6300C and densitometric analyses were conducted using Image-J software obtained from NIH image systems. The values are expressed as the mean Ϯ SEM. Normalized PARP protein levels in the sALS and control groups were analyzed with the two-tailed Student t-test with unequal variances using Excel software. Differences were considered statistically significant with p values of 0.05 or less.
Measurement of PARP mRNA in Spinal Cord Samples
Total RNA was extracted (RNAeasy, Qiagen, Valencia, CA) from homogenized frozen whole spinal cord samples or from dissected white or gray matter regions. The RNA concentrations were determined spectrophotometrically (Beckman DU-64, Fullerton, CA). RT-PCR was performed using 10 ng of RNA according to the manufacturer's instructions (OneStep RT-PCR, Qiagen) using an Eppendorph Mastercycler (Westbury, NY). The PARP primers were designed using Primer 3 software (Baylor College of Medicine, Houston, TX) and were as follows: forward 5Ј-GCATCCTCTGAGTGGCCAGAA-3Ј and reverse 5Ј-TCCGGGACTGACTGCAAAGAG-3Ј. The PCR protocol was 50ЊC for 30 min, 95ЊC for 15 min; (denatured at 95ЊC for 1 min, annealed at 60ЊC for 1 min, and extended at 72ЊC for 1 min 30 s) for 30 cycles; then 72ЊC for 5 min, and finally held at 4ЊC. The ␤-actin primers were 5Ј-GTGGGGCGCCCCA-GGCACCA-3Ј and 5Ј-CTCCTTAATGTCACGCACGATTTC-3Ј Graphed quantitative data expressing PARP-IR levels normalized to actin from the sALS (n ϭ 8) and control (n ϭ 5) groups. PARP expression in the spinal cord of sALS patients was significantly larger than in controls (2.8-fold increase; p Ͻ 0.0000024). Each patient's data was represented by the average of 3 independent experiments. Data are reported as group means Ϯ SEM.
as the forward and reverse primers, respectively (50) . The ␤-actin PCR conditions were 50ЊC for 30 min, 95ЊC for 15 min; (denatured at 95ЊC for 1 min, annealed at 57ЊC for 1 min, and extended at 72ЊC for 1 min 30 s) for 38 cycles; then 72ЊC for 5 min, and finally held at 4ЊC. The RT-PCR products were resolved by 1.5% agarose/ethidium bromide gel electrophoresis and photographed under UV illumination. The negatives were scanned with an HP ScanJet 6300C and densitometric analyses were performed using the Image J software. Group means were analyzed with the two-tailed Student t-test with unequal variances using Excel software and plotted Ϯ SEM; p values of 0.05 or less were considered statistically significant. 
PARP Immunohistochemistry
Spinal cord samples were fixed in 10% neutral formaldehyde and embedded in paraffin. Five-m-thick sections were cut from the blocks, deparaffinized, rehydrated, rinsed in tris-buffered saline (TBS, 50 mM; Sigma), and blocked for endogenous peroxidase activity (0.3% H 2 O 2 /methanol, 30 min). For antigen retrieval, sections were rinsed in TBS, placed in Na-citrate buffer (10 mM, pH 6.0; Sigma), and microwaved (3 ϫ 5 min at 600 watts). To block nonspecific IgG binding, sections were cooled to RT, washed in TBS, and incubated for 20 min. in TBS containing 2% normal horse serum (Vector Laboratories, Burlingame, CA). Sections were incubated overnight at 4ЊC with a mouse monoclonal anti-human PARP antibody (Serotec, Raleigh, NC) according to the manufacturer's recommendations (1/100 dilution in TBS). Sections were rinsed in TBS and incubated in biotin-labeled horse-anti-mouse IgG (Vector Laboratories) (1/200 dilution in TBS, containing 2% normal horse serum) for 30 min at RT, rinsed in TBS, and further incubated in a biotin-avidin complex for 30 min (Vector Elite kit; Vector Laboratories), followed by washing in TBS. The immunoreaction was developed using an enhanced DAB substrate kit for 15 min (Pierce, Rockford, IL) and washed in distilled water. Sections were dehydrated, cleared in xylene, and coverslipped.
Immunostained sections were examined under a Zeiss Axioskop microscope (Karl Zeiss, Oberkochen, Germany) equipped with a DXC-970-MD CCD camera (Sony Corp., Japan) and a digital image analysis system (Optimas 6.2; Optimas Corp., Bothell, WA). Numbers of immunostained profiles (cell nuclei) in the white matter (lateral column) and gray matter (ventral horn) in sALS spinal cords versus controls were measured after setting the threshold for background staining. All imaging parameters (i.e. recording and illumination settings) were kept constant throughout the evaluation of the whole series. Eight fields were analyzed, 4 at the ventral horn and 4 at the lateral column. The average of the number of positive profiles was used to characterize the PARP-IR of the gray matter and the white matter of the spinal cord for each patient.
In addition, sections were double stained for glial fibrillary acidic protein (GFAP) and PARP to determine if astrocytes express increased PARP-IR. Following antigen retrieval and blocking nonspecific IgG binding sites, the sections were incubated with the PARP antibody (1:100 dilution; Serotec) and with 1:200 dilution of rabbit anti-cow GFAP antibody (DAKO A/S, Glostrup, Denmark) overnight at 4ЊC. Texas red labeled affinity purified goat anti-rabbit IgG and FITC conjugated horse anti-mouse affinity purified IgG (both from Vector Laboratories) were used as secondary antibodies.
RESULTS
PARP Levels in Spinal Cords of Patients with sALS
To determine if the level of PARP-IR was increased in sALS tissue, PARP protein from 8 sALS and 5 non-neurological disease control spinal cord tissue was assayed by Western analyses. Although 2 different antibodies were used initially to ensure we were detecting PARP; the majority of the analyses were performed with 7D3-6. Equivalent results were seen with both antibodies. Representative Western blots (Fig. 1A) demonstrate that PARP-IR was increased in the sALS spinal cord when compared with control. The quantified, normalized, and pooled data of the sALS and control patients (Fig. 1B) revealed that PARP-IR was 2.8-fold higher in sALS than controls (p ϭ 0.0000024).
Caspase-3 Activation in the Spinal Cord
To examine whether pro-or activated caspase 3 expression was altered in sALS compared with control tissues, immunoblot analyses were performed with 4 sALS and 4 non-neurological disease control spinal cord samples using 2 different caspase-3 antibodies (CPP32 and CM 1 ). To control for recognition of activated caspase-3 by both antibodies, recombinant activated caspase-3 was used and could be recognized at ϳ17 kDa by both CPP32 and CM 1 (data not shown). Procaspase-3 immunoreactivity was readily detected in both sALS and control tissues; however, the immunoreactivity was similar in the 2 groups ( Fig. 2A, B) . No activated caspase-3 was detected in the spinal cord from sALS patients or controls using either antibody; however, the tissues we examined were harvested and frozen with an average delay of approximately 10 h postmortem.
Expression of PARP mRNA in the Spinal Cord
To ascertain whether the increase in PARP protein was due to an increase in PARP mRNA expression, spinal cords of sALS patients and controls were examined using semiquantitative RT-PCR. While the mRNA levels were examined in autopsy tissue, all of the levels were normalized with the internal control ␤-actin, which would control for mRNA integrity. Despite the increased levels of PARP protein in postmortem sALS tissue, no significant increase of the levels of PARP mRNA was detected (p ϭ 0.16) (Fig. 3A, B) . Thus the increased PARP protein detected in sALS tissue was not due to an increase in either PARP's transcription rate or mRNA stability.
Immunohistochemical Distribution of PARP-IR
To determine which cell types express the PARP-IR, we immunohistochemically examined spinal cord sections from sALS and control patients. PARP-IR was widespread in cells of control spinal cords, with higher density of stained profiles in the white matter than in the gray matter. In sALS spinal cords, the number of PARPimmunoreactive cellular profiles was increased in both white and gray matter. However, the variability of this increase from patient-to-patient was larger in the gray matter than in the white matter. In both sALS and control sections, nuclei of both glial and neuronal cells were the primary structures stained (Fig. 4E-H) . The PARP-IR was predominantly in cells with glial morphology, typically astrocytic morphology. Double immunostaining for PARP and for GFAP demonstrated that most of the PARP-immunoreactive cells in the white matter were astrocytes (Fig. 5B) .
Quantitative analyses were performed to determine the number of stained profiles in tissue domains of equal size in the gray and white matter of sALS and control spinal cord sections. Increased PARP-IR was present in the white matter of sALS spinal cords compared with controls, predominantly in cells with glial morphology (Fig.  5C ). Increased PARP-IR, also predominantly in cells with glial morphology, was present in the gray matter of sALS sections as well, but was far more variable (Fig. 5C ). Proportionately larger increases were present in the gray matter (2.7ϫ) than in the white matter (1.8ϫ), but only the latter was statistically significant (p Ͻ 0.016).
PARP staining of motor neurons was examined in sALS and control spinal cord sections. Motor neurons were identified according to their size and position in the ventral horn. Those motor neurons with readily discernible nuclei were assessed for PARP immunostaining (Fig.  6A, B) . Thirty-nine control neurons and 36 ALS neurons were counted. PARP-positive motor neurons were less frequently detected in sALS sections than in control sections. As a percentage of motor neurons counted, the control sections contained 75.5% Ϯ 3.7% PARP-positive motor neurons, while sALS sections had 23.8% Ϯ 11.0% PARP-positive motor neurons ( Fig. 6C ; p Ͻ 0.0014).
PARP Levels in Spinal Cords of Patients with sALS
Parallel Western and semiquantitative RT-PCR analyses were performed on sALS and control white and gray matter spinal cord specimens. PARP-IR was increased in the white matter of sALS spinal cord compared with control (p ϭ 0.04), but not in the gray matter (p ϭ 0.53) (Fig. 7A) . Interestingly, PARP mRNA expression was not significantly increased in the white (p ϭ 0.32) or the gray matter (p ϭ 0.62) of sALS tissue compared with control tissue (Fig. 7B) . Thus, the increase in PARP expression seen in the sALS tissue is not due to a significant increase in PARP transcription or mRNA stability, but is due to a net increased rate of translation, increased protein stability, and/or decreased protein degradation.
Distribution of PARP Expression in the Soluble and Pellet Fractions
To examine whether the increased PARP-IR in sALS might be related to altered distribution (and perhaps stabilization) of PARP protein, we compared levels of PARP-IR in whole spinal cord homogenate, soluble, and pellet fractions from sALS and control patients. We performed 2 fractionation studies. In the first study we examined equal amounts of protein from each fraction. Figure 8A shows an immunoblot evaluating 150 g protein from the total homogenate (H) and 150 g protein from each of the soluble (S) and pellet (P) fractions. PARP-IR in the sALS sample was dramatically increased in the pellet fraction and decreased in the soluble fraction when compared with the control sample. In the second fractionation study, we examined how PARP separated into soluble and pellet fractions from a specific amount of spinal cord homogenate. One 250-g aliquot of homogenate was separated into soluble (S) and pellet (P) fractions and compared with an identical unseparated 250-g aliquot. As shown in Figure 8B , a short 30-s exposure revealed increased PARP-IR in whole homogenate and pellet fractions in sALS compared with controls. A 10-min exposure further revealed PARP-IR was decreased in soluble fraction of sALS compared with controls. In the pellet fraction, PARP-IR was increased by 78% in the sALS sample compared with the control sample. In the soluble fraction, PARP-IR was decreased by 50% in the sALS sample compared with the control sample (Fig.  8C) .
DISCUSSION
Recent demonstrations of the presence of markers for oxidative stress in the CNS of sALS patients suggest a putative role for oxidative damage in ALS pathogenesis (2-5, 7, 8, 12-14) . Oxidative stress can induce DNA strand breaks, which subsequently triggers the activation of PARP (19) (20) (21) (23) (24) (25) . Alzheimer disease and MPTPinduced Parkinson disease are associated with increased oxidative stress and display increased PARP-and PARimmunostaining in affected brain tissue (34, 38) . Therefore, to determine if PARP expression was also increased in sALS spinal cord tissue, we evaluated the levels of PARP in postmortem tissue of sALS and non-neurological disease control patients. As with Alzheimer and MPTP-induced Parkinson diseased tissue, we demonstrated increased PARP-IR in sALS tissue compared with control.
To examine whether pro-or activated caspase 3 expression was altered in sALS compared with control tissues, immunoblot analyses were performed with sALS and control spinal cord samples using 2 different caspase-3 antibodies (CPP32 and CM 1 ). Procaspase-3 immunoreactivity was readily detected in both sALS and control tissues; however, the immunoreactivity was similar in the 2 groups. No activated caspase-3 was detected in the spinal cord from sALS patients or controls using either antibody; however, the tissues we examined were harvested and frozen with an average delay of approximately 10 h postmortem.
After observing the results of the immunoblot, we anticipated that the increased PARP immunoreactivity would reflect enhanced expression in neurons, perhaps in response to single strand DNA breaks due to increased oxidative stress and/or to increased intracellular Ca ϩϩ . However, our immunohistochemical studies demonstrated that the 3-fold increase PARP-IR noted in Western blots Homogenized tissue samples from sALS and control patients were divided into 2 aliquots. The first aliquot from each group was separated into the soluble (S) and pellet (P) fractions and 150 mg of protein of each were loaded into a gel for Western analysis. One hundred fifty g of protein from the second unseparated aliquot was also loaded (H). Blots were probed with anti-PARP monoclonal antibody (7D3-6). Standard molecular weight markers in kilodaltons are indicated. B: Homogenized tissue samples from sALS and control patients were divided into 2 aliquots, each containing 250 g protein. The first aliquot was separated into the soluble (S) and pellet (P) fractions and loaded in their entirety. The second 250-g aliquot was also loaded in its entirety (H). Blots were probed with anti-PARP monoclonal antibody (7D3-6). ECL signals were compared after 30 s and 10 min of exposure times. In the 30-s ECL exposure, PARP-IR of the whole homogenate (similar to that shown in Fig. 1 ) and the pellet fraction were already visible (upper panels), however, detection of soluble fractions required 10 min of exposure time (middle panels). The same membranes were stripped and reprobed with anti-actin antibody for normalization. Standard molecular weight markers in kilodaltons are indicated. The results from (A) and (B) suggest that PARP may be binding to membranes and/or chromatin, which could perhaps stabilize the PARP protein. C: Percent of PARP-IR is expressed for homogenate, supernatant, and pellet. from sALS spinal cord specimens was a reflection of glial rather than neuronal PARP-IR. The morphology of cells with increased PARP-IR suggested that astrocytes were the predominant cell type stained, and double antibody staining for PARP and GFAP confirmed that astrocytes were the most common cell type expressing PARP-IR. This staining pattern in sALS tissue is different from the pattern of PARP immunostaining seen in Lewy body disease, where neurons contained the most intense PARP-IR (51) and different from the PARP and PAR immunostaining seen in tissues from Alzheimer or MPTPinduced Parkinson patients, where neurons were the most common cell type containing PAR-IR and astrocytes contained the least (34, 38) . Although only PAR-IR was examined in the MPTP-induced Parkinson tissues, it is a reflection of PARP activity.
Although PARP-IR was increased in sALS spinal cord tissue, the mRNA for PARP was not increased significantly in the same specimens. If the increase PARP protein were due to astrogliosis, the increased astrocytic cell division would result in an increase in PARP mRNA; however, that was not the case. Several reasons why the PARP protein would be elevated, without an increased mRNA level, are an increased translation rate, increased protein stability, or slowed degradation, none of which can be directly examined in postmortem tissue. To determine if an altered distribution of PARP could explain the increased PARP-IR, we examined the distribution of PARP-IR in soluble and pellet fractions. We noted that the pellet PARP-IR was largely increased in sALS compared with control samples, while the soluble PARP-IR was decreased in sALS compared with control samples. The enhanced binding of PARP to the pellet fraction in sALS tissues (perhaps to chromatin, nuclear cytoskeleton, and/or nuclear membranes) could potentially stabilize the protein and/or protect it from degradation, and could explain the increased PARP-IR in the absence of a significant increase in PARP mRNA. PARP is known to interact with chromatin, centrosomes, transcription factors, cdk2, and p53 (52) (53) (54) Figure 5a shows enhanced PARP staining of the nuclear membrane and other structures in the nucleus. PARP is probably not binding to the protein aggregates seen in the cytoplasm and not the nucleus of ALS tissues (12, (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) (69) , unless the PARP immunoreactivity in the aggregate is somehow blocked.
Given that neurons were the most common cell type expressing PARP and PAR-IR in Alzheimer (38) and MPTP-induced Parkinson (34) disease tissue, diseases also associated with increased oxidative stress; the decreased PARP-IR staining of large motor neurons in sALS was unexpected. It is possible that spinal motor neurons respond differently to oxidative stress than brain neurons affected in Alzheimer disease and Parkinson disease. Since we were examining postmortem tissue, it is also possible that PARP is increased in motor neurons early in the disease and decreases in terminal stages of sALS. It has been shown that measures of oxidative stress in the animal model for ALS (mSOD1) are increasing as the disease progresses (15, 70, 71) . Perhaps PARP expression increases until excessive PARP activation leads to energy depletion, resulting in a protective suppression of PARP expression. Such a protective response might suppress the expression of PARP to conserve energy in nonproliferating cells. Surviving motor neurons in sALS would then be able to give priority to essential ATP-dependent processes. However, we cannot rule out the possibility that PARP expression was never increased in sALS motor neurons. PARP has been reported to mediate NMDA but not non-NMDA excitotoxicity (46) , and the major glutamate receptor in motor neurons is the AMPA/ Kainate receptor (72) (73) (74) (75) (76) (77) (78) . However, some large motor neurons expressing increased PARP-IR were present in the sALS tissues, arguing against neuronal PARP never increasing in motor neurons. Studies in the sALS transgenic animal model (mSOD1) may help clarify the expression levels of PARP as the disease progresses and the mechanisms modulating its expression in motor neurons.
Recently, treatment with a PARP inhibitor beginning on day 28 resulted in a nonsignificant (p ϭ 0.08) trend toward increased survival of the mSOD1 mouse (4% increase) (79) . On the basis of our findings, one could speculate that if PARP expression was downregulated in motor neurons at 30 to 40 days, no additional benefit would be obtained by the continued administration of PARP inhibitors. However, no benefit would occur if PARP expression were never increased in sALS motor neurons. Further studies are essential to define the significance and time frame of the enhanced PARP-IR in glia, as well as how and why PARP-IR may be downregulated in sALS motor neurons.
PARP can be activated by single or double-strand breaks in DNA (80) (81) (82) , and the present demonstration of increased expression of this DNA repair enzyme in sALS is in agreement with previous reports of oxidative damage to DNA and other macromolecules in sALS (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Furthermore, the increased PARP-IR in glia in sALS is in accord with other demonstrations of alterations of astrocytes in response to oxidative stress in ALS (8, 14, 15, 17, 18) and in other systems (83) (84) (85) , including alterations in the glutamate transporter, GLT-1 or EAAT2 (8, 18, (86) (87) (88) (89) . Excessive oxidative stress can result in increased PARP expression in astrocytes and can ultimately result in energy depletion and death of the astrocyte (25, 29, 32, 90, 91) . Since astroglia may represent an important source of antioxidant protection (92) (93) (94) (95) and neurotrophic factors (93) (94) (95) (96) , the increased PARP-IR in glia may indicate a somewhat compromised ability to mediate critical neuroprotective functions. At the very least, these data demonstrate that the pathological process is not limited to neurons but involves glia in a significant way.
